Pancreatic Disorders News

Patients with pancreatic adenocarcinoma who had a high Khorana score or elevated blood urea nitrogen at baseline demonstrated a significantly greater risk for mortality within 6 months after surgical resection, according to study results.

The FDA has released updated information for health care providers regarding the safety of endoscopic retrograde cholangiopancreatography, or ERCP, duodenoscopes.

The manufacturer of a duodenoscope involved in the recent carbapenem-resistant Enterobacteriaceae outbreak at Ronald Reagan UCLA Medical Center did not have 510(k) clearance, according to a statement from the FDA.

The FDA has granted 510(k) clearance to the SpyGlass DS Direct Visualization System for cholangioscopy and pancreatoscopy procedures, updated from the original model to improve ease of setup, ease of use and image quality, the manufacturer announced.

The complex design of endoscopic retrograde cholangiopancreatography duodenoscopes may cause challenges for effective cleaning and disinfection, according to an FDA safety communication released today.

PancraGen, an integrated molecular pathology test that combines molecular analysis with clinical test results to assess the malignant potential of pancreatic cysts, provided more accurate results compared with management recommended by current guidelines in a recent trial.

Patients with locally advanced, unresectable pancreatic adenocarcinoma experienced favorable survival when they received neoadjuvant gemcitabine, docetaxel and capecitabine, according to study results.

In a new retrospective analysis, solid organ transplantation saved more than 2 million life-years, including more than 400,000 among liver transplant recipients, during a 25-year period, according to new study data published in JAMA Surgery.

The European Commission has granted orphan drug designation to pegylated recombinant human hyaluronidase, or PEGPH20, for treatment of pancreatic cancer, the manufacturer announced.

The FDA granted fast track designation to the investigation of necuparanib for treatment of patients with metastatic pancreatic cancer, according to a press release from the manufacturer.